Literature DB >> 21735468

The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice.

Yan-Dong Wang1, Wei-Dong Chen, Donna Yu, Barry M Forman, Wendong Huang.   

Abstract

UNLABELLED: Gpbar1 (TGR5), a membrane-bound bile acid receptor, is well known for its roles in regulation of energy homeostasis and glucose metabolism. TGR5 also displays strong attenuation of macrophage reactivity in vitro, but the physiological roles of TGR5 in inflammatory response, and its mechanism, is unknown. Here, we demonstrate that TGR5 is a negative modulator of nuclear factor kappa light-chain enhancer of activated B cells (NF-κB)-mediated inflammation. TGR5 activation suppresses the phosphorylation of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα), the translocation of p65, NF-κB DNA-binding activity, and its transcription activity. Furthermore, TGR5 activation enhances the interaction of IκBα and β-arrestin2. Suppression of NF-κB transcription activity and its target gene expression by TGR5 agonist are specifically abolished by the expression of anti-β-arrestin2 small interfering RNA. These results show that TGR5 suppresses the NF-κB pathway by mediation of the interaction between IκBα and β-arrestin2. In a lipopolysaccharide (LPS)-induced inflammation model, TGR5(-/-) mice show more severe liver necroses and inflammation, compared with wild-type (WT) mice. Activation of TGR5 by its agonist ligand inhibits the expression of inflammatory mediators in response to NF-κB activation induced by LPS in WT, but not TGR5(-/-), mouse liver.
CONCLUSION: These findings identify TGR5 as a negative mediator of inflammation that may serve as an attractive therapeutic tool for immune and inflammatory liver diseases.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735468      PMCID: PMC3184183          DOI: 10.1002/hep.24525

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  49 in total

Review 1.  Adenosine A2A agonists in development for the treatment of inflammation.

Authors:  Courtney M Lappas; Gail W Sullivan; Joel Linden
Journal:  Expert Opin Investig Drugs       Date:  2005-07       Impact factor: 6.206

2.  Bcl10 plays a critical role in NF-kappaB activation induced by G protein-coupled receptors.

Authors:  Donghai Wang; Yun You; Pei-Chun Lin; Liquan Xue; Stephan W Morris; Hu Zeng; Renren Wen; Xin Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-19       Impact factor: 11.205

Review 3.  Inflammation and metabolic disorders.

Authors:  Gökhan S Hotamisligil
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

4.  Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation.

Authors:  Galya Vassileva; Andrei Golovko; Lisa Markowitz; Susan J Abbondanzo; Ming Zeng; Shijun Yang; Lizbeth Hoos; Glen Tetzloff; Diane Levitan; Nicholas J Murgolo; Kevin Keane; Harry R Davis; Joseph Hedrick; Eric L Gustafson
Journal:  Biochem J       Date:  2006-09-15       Impact factor: 3.857

5.  Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice.

Authors:  Takaharu Maruyama; Kenichi Tanaka; Jun Suzuki; Hiroyuki Miyoshi; Naomoto Harada; Takao Nakamura; Yasuhisa Miyamoto; Akio Kanatani; Yoshitaka Tamai
Journal:  J Endocrinol       Date:  2006-10       Impact factor: 4.286

6.  New insights into the regulation of inflammation by adenosine.

Authors:  Joel Linden
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

Review 7.  From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors.

Authors:  Fulvio D'Acquisto; Angela Ianaro
Journal:  Curr Opin Pharmacol       Date:  2006-06-14       Impact factor: 5.547

8.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.

Authors:  Mitsuhiro Watanabe; Sander M Houten; Chikage Mataki; Marcelo A Christoffolete; Brian W Kim; Hiroyuki Sato; Nadia Messaddeq; John W Harney; Osamu Ezaki; Tatsuhiko Kodama; Kristina Schoonjans; Antonio C Bianco; Johan Auwerx
Journal:  Nature       Date:  2006-01-08       Impact factor: 49.962

9.  Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.

Authors:  Gideon M Hirschfield; J Ruth Gallimore; Melvyn C Kahan; Winston L Hutchinson; Caroline A Sabin; G Martin Benson; Amar P Dhillon; Glenys A Tennent; Mark B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

10.  Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury.

Authors:  Chun-Xiao Sun; Hongyan Zhong; Amir Mohsenin; Eva Morschl; Janci L Chunn; Jose G Molina; Luiz Belardinelli; Dewan Zeng; Michael R Blackburn
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

View more
  157 in total

1.  TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation.

Authors:  Alessia Perino; Thijs Willem Hendrik Pols; Mitsunori Nomura; Sokrates Stein; Roberto Pellicciari; Kristina Schoonjans
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

2.  Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes.

Authors:  Elaine Studer; Xiqiao Zhou; Renping Zhao; Yun Wang; Kazuaki Takabe; Masayuki Nagahashi; William M Pandak; Paul Dent; Sarah Spiegel; Ruihua Shi; Weiren Xu; Xuyuan Liu; Pat Bohdan; Luyong Zhang; Huiping Zhou; Phillip B Hylemon
Journal:  Hepatology       Date:  2011-11-30       Impact factor: 17.425

Review 3.  Role of bile acids in the regulation of the metabolic pathways.

Authors:  Hiroki Taoka; Yoko Yokoyama; Kohkichi Morimoto; Naho Kitamura; Tatsuya Tanigaki; Yoko Takashina; Kazuo Tsubota; Mitsuhiro Watanabe
Journal:  World J Diabetes       Date:  2016-07-10

Review 4.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

Review 5.  Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.

Authors:  John Y L Chiang; Jessica M Ferrell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-27       Impact factor: 4.052

6.  Previous physical exercise alters the hepatic profile of oxidative-inflammatory status and limits the secondary brain damage induced by severe traumatic brain injury in rats.

Authors:  Mauro Robson Torres de Castro; Ana Paula de Oliveira Ferreira; Guilherme Lago Busanello; Luís Roberto Hart da Silva; Mauro Eduardo Porto da Silveira Junior; Fernando da Silva Fiorin; Gabriela Arrifano; Maria Elena Crespo-López; Rômulo Pillon Barcelos; María J Cuevas; Guilherme Bresciani; Javier González-Gallego; Michele Rechia Fighera; Luiz Fernando Freire Royes
Journal:  J Physiol       Date:  2017-07-30       Impact factor: 5.182

7.  Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Cunbao Li; Cong Guo; Yanyan Li; Hui Qi; Hailing Shen; Jing Kong; Xuecheng Long; Frank Yuan; Xichun Wang; Wendong Huang
Journal:  Mol Endocrinol       Date:  2014-12-12

8.  Bile Acid Receptors and Liver Cancer.

Authors:  Xichun Wang; Xianghui Fu; Carl Van Ness; Zhipeng Meng; Xiaoxiao Ma; Wendong Huang
Journal:  Curr Pathobiol Rep       Date:  2012-12-21

Review 9.  Functions of innate immune cells and commensal bacteria in gut homeostasis.

Authors:  Hisako Kayama; Kiyoshi Takeda
Journal:  J Biochem       Date:  2015-11-27       Impact factor: 3.387

10.  The TGR5 receptor mediates bile acid-induced itch and analgesia.

Authors:  Farzad Alemi; Edwin Kwon; Daniel P Poole; TinaMarie Lieu; Victoria Lyo; Fiore Cattaruzza; Ferda Cevikbas; Martin Steinhoff; Romina Nassini; Serena Materazzi; Raquel Guerrero-Alba; Eduardo Valdez-Morales; Graeme S Cottrell; Kristina Schoonjans; Pierangelo Geppetti; Stephen J Vanner; Nigel W Bunnett; Carlos U Corvera
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.